Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: RNA based therapeutics - miRecule

Next Previous
Drug Profile

Research programme: RNA based therapeutics - miRecule

Alternative Names: MIR 101; MIR-101 - miRecule; miR-30-5p mimic

Latest Information Update: 07 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator miRecule
  • Class Antineoplastics; Antivirals; MicroRNAs; Oligoribonucleotides; RNA; RNA binding proteins
  • Mechanism of Action MicroRNA modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research COVID 2019 infections; HIV infections
  • No development reported Head and neck cancer

Most Recent Events

  • 07 Jun 2021 miRecule has patent protection for RNA chemistry to develop RNA therapeutics before May 2021 (miRecule website, June 2021)
  • 27 May 2021 Early research in COVID-2019 infections in USA (Parenteral)
  • 27 May 2021 Early research in HIV infections in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top